The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched its Registry for SIR-Spheres Therapy (CIRT) to capture information on patients who have been treated with SIR-Spheres yttrium-90 (Y-90) resin microspheres for inoperable liver tumors.
The registry, developed in collaboration with SIR-Spheres Y-90 resin microsphere manufacturer Sirtex Medical, aims to enter treatment data on more than 500 patients a year from more than 20 specialist European hospitals. The microspheres are the only product used for selective internal radiation therapy, CIRSE said.
